Interaction Checker

Wechselwirkungen von Riluzol

Riluzol (Rilutek, Tiglutik, Exservan) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 36 dokumentierte Wechselwirkungen: 0 schwerwiegende, 33 mittelschwere, 3 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Mittelschwere Wechselwirkungen (33)

  • Cannabidiol (verschreibungspflichtig)AntiepileptikumMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • CarbamazepinAntiepileptikumMittelschwer

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • CimetidinH2-BlockerMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • CiprofloxacinFluorchinolonMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • DeferasiroxEisenpräparatMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Desogestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Drospirenon und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • EstradiolEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Estradiol und Dienogestorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Estradiol und NorethisteronEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Etonogestrel und EthinylestradiolEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Etynodioldiacetat und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • FluvoxaminSSRIMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • FulvestrantEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Konjugierte EstrogeneEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Konjugierte Estrogene und BazedoxifenEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • LevonorgestrelGestagenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Levonorgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • MedroxyprogesteronGestagenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • MegestrolGestagenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • MexiletinAntiarrhythmikumMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • MifepristonCYP3A4-HemmerMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Norelgestromin und EthinylestradiolEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • NorethisteronGestagenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Norethisteron und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Norgestimat und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Norgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • ProgesteronGestagenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • Veresterte Estrogene und MethyltestosteronEstrogenMittelschwer

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • ViloxazinNoradrenalin-WiederaufnahmehemmerMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • ZileutonCYP1A2-HemmerMittelschwer

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

Geringfügige Erwähnungen (3)

  • AllopurinolXanthinoxidasehemmerGeringfügig

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • MethyldopaAntihypertensivumGeringfügig

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

  • SulfasalazinSulfonamidGeringfügig

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (Fachinformation zu Riluzol, Arzneimittelwechselwirkungen)

Prüfen Sie Riluzol gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.